Physician profile
Paula A Bessonett
NPI 1144209354
$632.36
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $59.56 · 2021: $123 · 2022: $67.28 · 2023: $42.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $247.61 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $87.86 | 2019 | |
| Abbvie INC. | $87.60 | 2021-2023 | Vraylar, Qulipta |
| Novo Nordisk INC | $66.72 | 2020-2021 | |
| Amgen INC. | $36.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.94 | 2021-2022 | |
| Mylan Specialty L.P. | $23.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2021 | |
| Lilly USA, LLC | $16.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Bessonett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.